A combination therapy delays HIV viral rebound study

首页

2018-10-04

AnewstudypublishedinNatureonWednesdayshowedthatadministeringantibodiesdesignedtotargetHIVincombinationwithagentsthatstimulatetheinnateimmunesystemdelayedviral(BIDMC)suggestedthatthistwo-prongedapproachrepresentsapotentialstrategyfortargetingtheviralreservoiroussabilitytobecomedormant,remainingpresentbutsilentinimmunecells."ThelatentviralreservoiristhecriticalbarrierforthedevelopmentofacureforHIV-1infection,",steamstudied44rhesusmonkeysinfectedwithanHIV-likevirusandtreatedwithARTfortwoandahalfyears,,theyweredividedintoacontrolgroupwithoutadditionaltreatments,twogroupswhoweregivenonlyanimmunestimulatingagentoronlythebroadlyneutralizingantibodies(bNAb)andaf,atwhichpointthescientistsbeganmonitoringtheanimalsbloodforsignsofthevirussreturn,lyandwithhighpeakviralloads,,fiveof11monkeysdidnotreboundwithinsixmonths,,thosethatdidreboundshowedmuchlowerpeakviralloadscomparedtothecontrolanimals."ThecombinationoftheantibodiesandtheimmunestimulantledtooptimalkillingofHIV-infectedcells,"saidBarouch,whoisalsoProfessorofMedicineatHarvardMedicalSchool."Thisstudyprovidesaninitialproof-of-conceptshowingapotentialstrategytotargettheviralreservoir,"saidBarouch.。